Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Microsoft to accelerate the early detection of lung cancer by integrating advanced artificial intelligence tools into routine radiology workflows across the United States. The partnership brings together BMS’s oncology expertise and Microsoft’s leadership in AI-powered radiology and clinical workflow technologies, with the shared goal of identifying lung cancer at earlier, more treatable stages.
Under the agreement, U.S. Food and Drug Administration–cleared radiology AI algorithms will be deployed through Microsoft’s Precision Imaging Network, a core component of Microsoft for Healthcare’s radiology solutions. The network is already widely adopted, with more than 80% of U.S. hospitals using it to securely share medical imaging and access third-party imaging AI tools. These algorithms are designed to automatically analyze chest X-rays and CT scans, helping radiologists detect subtle lung abnormalities, including hard-to-identify lung nodules that may indicate early-stage disease.
Lung cancer remains the leading cause of cancer-related deaths in the United States, accounting for an estimated 125,000 deaths and approximately 227,000 new cases each year. Outcomes are particularly poor among medically underserved populations, who face higher mortality rates and lower access to guideline-recommended screening. Compounding the challenge, more than half of patients with incidental lung findings are lost to follow-up, delaying diagnosis and treatment.
The BMS–Microsoft collaboration seeks to address these gaps by pairing AI-driven image analysis with workflow management tools that can track patients with lung nodules throughout their care journey. By ensuring consistent follow-up and timely referrals, the initiative aims to reduce missed diagnoses and improve care coordination.
BMS executives emphasized that the collaboration supports both clinical efficiency and health equity. By extending AI-enabled detection tools to rural hospitals and community clinics, the initiative is designed to bring advanced diagnostic capabilities to resource-limited settings, where specialist access may be constrained.
Microsoft highlighted that its AI-powered radiology platform operates seamlessly in the background of existing healthcare systems, enabling clinicians to identify potential cancer signals earlier—often before symptoms emerge. Together, the companies view the partnership as a scalable, sustainable approach to improving lung cancer outcomes while reducing disparities in access to early detection and care.